LOTUS PHARMACEUTICAL

Congress should investigate China for US investment losses
If most of these small cap Chinese companies start turning into scams or frauds, then that represents more than an SEC issue. That would represent an orchestrated transfer of billions of dollars from the US to China. At some point congress needs to get involved in investigating the situation with these small cap Chinese companies, because China is effectively stealing vast sums of wealth from US citizens.

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_L/threadview?m=tm&bn=42886&tid=6672&mid=6672&tof=4&frt=2

http://clinicaltrials.pharmaceutical-business-review.com/news/rbambuterol_clinical_trial_i_on_track_lotus_pharma_100830/

R-Bambuterol clinical trial I on track: Lotus Pharma

Published: 30-Aug-2010

Lotus Pharmaceuticals has reached R-Bambuterol clinical trial I as per the schedule and is on track to complete in six months.

In the trials, Lotus is expected to investigate the safety and tolerability and biological activity of R-Bambuterol by measuring responses in healthy volunteers.

Previously, in preclinical trials, R-Bambuterol Hydrochloride tablets demonstrated efficacy and less toxicity as an anti-asthma drug than Bambuterol currently available in the market.

R-Bambuterol clinical trials are co-monitored by Lotus and Beijing Zenith International Medical Science Technology Development Company Limited.

Lotus is a developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC).

Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial

Neue Tablette wird getestet , soll in 6 Monaten fertiggestellt werden...Kompletter Artikel bei "finanznachrichten.de" unter

http://www.finanznachrichten.de/nachrichten-2010-08/17799189-lotus-pharmaceuticals-enter-r-bambuterol-r-clinical-trial-i-008.htm

...it has entered R-Bambuterol(R) Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.

The studies are co-monitored by the Company and Beijing Zenith International Medical Science and Technology Development Company Limited, a mid-size full-service clinical research organization, and carried out in Peking University Third Hospital, a top-ranked AAA hospital recognized as a base adherence to the principles of good clinical practices (GCPs).

R-Bambuterol(R) Hydrochloride Tablets showed significant efficacy and less toxicity in preclinical trials as an anti-asthma drug than Bambuterol currently available in the market.

If it reaches the market, R-Bambuterol(R) Hydrochloride Tablets would address the Chinese asthma and chronic obstructive pulmonary disease (COPD) market led by AstraZeneca with a 26 percent share in 2009, according to IMS.

Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results

BEIJING, Aug. 16 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (BULLETIN BOARD: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), reported today its financial results for the quarter and six months ended June 30, 2010.

Second Quarter ("Q2") 2010 Highlights and Developments: -- Q2 diluted EPS of $0.12 vs. $0.10 for Q2 2009 -- Q2 net income increased 32% from Q2 2009 to $6.3 million -- Q2 gross margin of 52.3% compared to 57.9% in Q2 of 2009

Für den kompletten Artikel bei "Finanznachrichten.de" und Zahlen diesen Link klicken

http://www.finanznachrichten.de/nachrichten-2010-08/17705171-lotus-pharmaceuticals-reports-strong-second-quarter-2010-financial-results-008.htm